Abstract
BackgroundGiven the existing evidence that the degree of response to certolizumab pegol (CZP) at Week 12 is determinant of the probability of long-term response to CZP, a risk-sharing scheme (RSS)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have